Hasil Pencarian (1)
biotech | CAS: 1418205-77-2
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.[L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F.[A244455] It…
Kategori:
Agents reducing cytokine levelsAmino Acids, Peptides, and ProteinsAntibodies
+11
Target Protein:
Interleukin-17AInterleukin-17F
Waktu ParuhThe mean terminal e…
Vol. DistribusiIn patients with pl…
KlirensThe median apparent…
Genetik
-